Glutamatergic abnormalities of the thalamus in schizophrenia: a systematic review
- 26 February 2008
- journal article
- review article
- Published by Springer Nature in Journal Of Neural Transmission-Parkinsons Disease and Dementia Section
- Vol. 115 (3) , 493-511
- https://doi.org/10.1007/s00702-007-0859-5
Abstract
Summary. The thalamus, a key information processing centre in facilitating sensory discrimination and cognitive processes, has been implicated in schizophrenia due to the increasing evidence showing structural and functional thalamic abnormalities. Glutamatergic abnormalities, in particular, have been examined since glutamate is one of the main neurotransmitters found in the thalamus. We aimed to review the existing literature (1978 till 2007) on post-mortem and in vivo studies of the various components of glutamatergic neurotransmission as well as studies of the glutamate receptor genes within the thalamus in schizophrenia. The literature search was done using multiple databases including Scopus, Web of Science, EBSCO host, Pubmed and ScienceDirect. Keywords used were “glutamate”, “thalamus”, “schizophrenia”, “abnormalities”, and “glutamatergic”. Further searches were made using the bibliographies in the main journals and related papers were obtained. The extant data suggest that abnormalities of the glutamate receptors as well as other molecules involved in glutamatergic neurotransmission (including glutamate transporters and associated proteins, N-methyl D-aspartate (NMDA) receptor-associated intracellular signaling proteins, and glutamatergic enzymes) are found within the thalamus in schizophrenia. There is a pressing need for more rapid replication of findings from post mortem and genetic studies as well as the promotion of multi-component or multi-modality assessments of glutamatergic anomalies within the thalamus in order to allow a better appreciation of disruptions in these molecular networks in schizophrenia. These and future findings may represent potential novel targets for antipsychotic drugs to ameliorate the symptoms of schizophrenia.Keywords
This publication has 136 references indexed in Scilit:
- Distribution of NMDA and AMPA receptor subunits at thalamo-amygdaloid dendritic spinesBrain Research, 2007
- Testing models of thalamic dysfunction in schizophrenia using neuroimagingJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2005
- Variations in the NMDA receptor subunit 2B gene (GRIN2B) and schizophrenia: A case‐control studyAmerican Journal Of Medical Genetics Part B-Neuropsychiatric Genetics, 2004
- Family‐based association study of schizophrenia with 444 markers and analysis of a new susceptibility locus mapped to 11q13.3American Journal Of Medical Genetics Part B-Neuropsychiatric Genetics, 2004
- A microsatellite repeat in the promoter of the N-methyl-d-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophreniaPharmacogenetics, 2003
- N‐methyl‐d‐aspartate receptor NR1 subunit gene (GRIN1) in schizophrenia: TDT and case‐control analysesAmerican Journal Of Medical Genetics Part B-Neuropsychiatric Genetics, 2003
- Identification of single nucleotide polymorphisms (SNPs) and other sequence changes and estimation of nucleotide diversity in coding and flanking regions of the NMDAR1 receptor gene in schizophrenic patientsMolecular Psychiatry, 2001
- Mutation analysis of the NMDAR2B (GRIN2B) gene in schizophreniaMolecular Psychiatry, 2001
- Cortical Development and Thalamic Pathology in SchizophreniaSchizophrenia Bulletin, 1997
- Glutamate and schizophreniaTrends in Pharmacological Sciences, 1990